# A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

> **NCT00117676** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 382 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** TDF
- **DRUG:** ADV
- **DRUG:** TDF placebo
- **DRUG:** ADV placebo
- **DRUG:** FTC/TDF

## Key facts

- **NCT ID:** NCT00117676
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2007-04
- **Final completion:** 2016-01
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2017-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117676, "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00117676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*